Acadia Pharmaceuticals (ACAD) Leases (2019 - 2026)

Acadia Pharmaceuticals has reported Leases for 8 years, with the latest figure at $46.3 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 8.57% year-over-year to $46.3 million; the trailing twelve-month figure through Mar 2026 stood at $46.3 million (down 8.57% YoY), and the FY2025 full-year result was $47.4 million, up 1.68% from the prior year.
• Leases for Q1 2026 stood at $46.3 million, down from $47.4 million in the prior quarter.
• The five-year high for Leases was $58.2 million in Q1 2022, with the low at $44.3 million in Q3 2024.
• Average Leases over 5 years is $51.7 million, with a median of $51.9 million recorded in 2023.
• Year-over-year, Leases decreased 12.82% in 2024 and grew 12.25% in 2025.
• Tracing ACAD's Leases over 5 years: stood at $55.6 million in 2022, then fell by 6.69% to $51.9 million in 2023, then declined by 10.19% to $46.6 million in 2024, then grew by 1.68% to $47.4 million in 2025, then declined by 2.28% to $46.3 million in 2026.
• The last three Leases figures came in at $46.3 million (Q1 2026), $47.4 million (Q4 2025), and $49.7 million (Q3 2025), per Business Quant data.

Peer Comparison